Treatment with anti-vegf antibodies

Abstract

This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.

1 . A method of treating bladder cancer in a human patient, comprising administering to the patient effective amounts of an anti-VEGF antibody, wherein said anti-VEGF antibody is bevacizumab, and an at least one anti-neoplastic composition, wherein said anti-neoplastic composition comprises at least one chemotherapeutic agent.  
     
     
         2 . The method of  claim 1 , wherein the anti-VEGF antibody is administered concomitantly with the at least one chemotherapeutic agent.  
     
     
         3 . The method of  claim 1 , wherein the bladder cancer is metastatic.  
     
     
         4 . The method of  claim 1 , wherein the patient is previously untreated.  
     
     
         5 . The method of  claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodopyyllotoxins, antibiotics, L-Asparaginase, topoisomerase inhibitor, interferons, platinum cooridnation complexes, anthracenedione substituted urea, methyl hydrazine derivatives, adrenocortical suppressant, adrenocorticosteroides, progestins, estrogens, antiestrogen, androgens, antiandrogen, and gonadotropin-releasing hormone analog.  
     
     
         6 . The method of  claim 1 , wherein the anti-neoplastic composition comprises a combination of at least two chemotherapeutic agents.  
     
     
         7 . The method of  claim 1 , wherein the anti-VEGF antibody is administered intravenously.  
     
     
         8 . The method of  claim 1 , wherein the anti-VEGF antibody is administered to the patient at about 5 mg/kg to about 15 mg/kg every 2 to 3 weeks.  
     
     
         9 . The method of  claim 7 , wherein the administration is by intravenous infusion over 30-90 minutes.  
     
     
         10 . The method of  claim 1 , wherein said at least one chemotherapeutic agent is cisplatin, gemcitabine, an anti-metabolite, a vinca, adriamycin, or carboplatin.  
     
     
         11 . The method of  claim 10 , wherein the anti-metabolite is methotrexate.  
     
     
         12 . The method of  claim 10 , wherein the vinca is vinblastine.